PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1485794
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1485794
Plasmid DNA Manufacturing Market size was valued at USD 1,788.98 Million in 2023, expanding at a CAGR of 21.5% from 2024 to 2032.
The Global Plasmid DNA Manufacturing Market is seeing substantial expansion and transition, owing to advances in biopharmaceutical study and development. Plasmid DNA, a flexible molecular tool, serves as the basis for a wide range of therapeutic applications, including DNA vaccinations, cell and gene therapy. As the need for personalised medicine and targeted therapies continues to develop, the market for plasmid DNA synthesis is positioned to significantly expand.
Plasmid DNA Manufacturing Market- Market Dynamics
Increasing research and development activities and the rising prevalence of genetic disorders and infectious diseases propel market demand
A variety of reasons are driving the Plasmid DNA Manufacturing marketplace, including increased R&D efforts, increased biopharmaceutical investments, and the rising frequency of genetic abnormalities and infectious illnesses. Furthermore, the move towards precision medicine and the development of new immunotherapies are driving up demand for plasmid DNA-based medicines. Regulatory advances and shortened approval procedures boost market expansion, allowing speedier translation of research discoveries into clinical applications.
Plasmid DNA Manufacturing Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 21.5% over the forecast period (2024-2032)
Based on Grade segmentation, R&D Grade was predicted to show maximum market share in the year 2023
Based on application segmentation, DNA Vaccines was the leading type in 2023
Based on Development Phase segmentation, Pre-Clinical Therapeutics was the leading type in 2023
Based on region, North America was the leading revenue generator in 2023
The Global Plasmid DNA Manufacturing Market is segmented based on Grade, Application, Development Phase, Disease, and Region.
The market is divided into three categories based on Grade: R&D Grade, GMP Grade. The R&D Grade sector dominates the market. Widely used in early-stage research and development, R&D Grade plasmid DNA enables scientists to explore novel therapeutic concepts and validate preclinical efficacy.
The market is divided into two categories based on application: DNA Vaccines, Cell & Gene Therapy, Immunotherapy, and Others. The DNA vaccine segment dominates the market and is likely to maintain its dominance during the forecast period. Leveraging the immune system's ability to recognize and combat pathogens, DNA vaccines offer a promising approach to preventing infectious diseases and addressing emerging health threats.
Plasmid DNA Manufacturing Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.
The Plasmid DNA Manufacturing Market is competitive, with prominent competitors vying for supremacy via novel manufacturing processes and scalable production capacity. Companies use strategic alliances, acquisitions, and R&D expenditures to strengthen their market position and broaden their product offerings. Leading companies prioritise quality assurance, regulatory compliance, and cost-effective solutions to fulfil the expanding demand for plasmid DNA in a variety of applications, including gene therapy, vaccine research, and biopharmaceutical manufacturing. To sustain their competitive advantage, businesses must constantly adapt to changing market trends and client demands.
In February 2023, PackGene Biotech expanded its services with the opening of an innovative GMP biomanufacturing and processing plant in Houston, Texas. This comprises gene therapy programmes that produce cost-effective, dependable, and scalable AAV products. With this development, the business hopes to become a one-stop solution supplier for gene therapy developers.
GLOBAL PLASMID DNA MANUFACTURING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Nature Technology
Cell and Gene Therapy Catapult
Danaher (Aldevron)
Kaneka Corp.
Eurofins Genomics
Lonza
Charles River Laboratories
VGXI, Inc.
Luminous BioSciences, LLC
Akron Biotech
Others